Top

Published in:

01-06-2020 | Metastasis | Review

CXCL-10: a new candidate for melanoma therapy?

Authors: Hossein Bagheri, Mohammad Hossein Pourhanifeh, Maryam Derakhshan, Maryam Mahjoubin-Tehran, Faezeh Ghasemi, Shabnam Mousavi, Rouhollah Rafiei, Kazem Abbaszadeh-Goudarzi, Hamid Reza Mirzaei, Hamed Mirzaei

Published in: Cellular Oncology | Issue 3/2020

Abstract

Background

Melanoma is a malignancy that stems from melanocytes and is defined as the most dangerous skin malignancy in terms of metastasis and mortality rates. CXC motif chemokine 10 (CXCL10), also known as interferon gamma-induced protein-10 (IP-10), is a small cytokine-like protein secreted by a wide variety of cell types. CXCL10 is a ligand of the CXC chemokine receptor-3 (CXCR3) and is predominantly expressed by T helper cells (Th cells), cytotoxic T lymphocytes (CTLs), dendritic cells, macrophages, natural killer cells (NKs), as well as some epithelial and cancer cells. Similar to other chemokines, CXCL10 plays a role in immunomodulation, inflammation, hematopoiesis, chemotaxis and leukocyte trafficking.

Conclusions

Recent studies indicate that the CXCL10/CXCR3 axis may act as a double-edged sword in terms of pro- and anti-cancer activities in a variety of tissues and cells, especially in melanoma cells and their microenvironments. Most of these activities arise from the CXCR3 splice variants CXCR3-A, CXCR3-B and CXCR3-Alt. In this review, we discuss the pro- and anti-cancer properties of CXCL10 in various types of tissues and cells, particularly melanoma cells, including its potential as a therapeutic target.

Y. Le, Y. Zhou, P. Iribarren, J. Wang, Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cell Mol Immunol 1, 95–104 (2004)PubMed

A.J. Zweemer, J. Toraskar, L.H. Heitman, I.J. AP, Bias in chemokine receptor signalling. Trends Immunol 35, 243–252 (2014). https://doi.org/10.1016/j.it.2014.02.004 CrossRefPubMed

H. Nomiyama, N. Osada, O. Yoshie, Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells 18, 1–16 (2013). https://doi.org/10.1111/gtc.12013 CrossRefPubMed

A.D. Luster, J.V. Ravetch, Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166, 1084–1097 (1987). https://doi.org/10.1084/jem.166.4.1084 CrossRefPubMed

J.R. Groom, A.D. Luster, CXCR3 ligands: Redundant, collaborative and antagonistic functions. Immunol Cell Biol 89, 207–215 (2011). https://doi.org/10.1038/icb.2010.158 CrossRefPubMed

K.D. Dyer, C.M. Percopo, E.R. Fischer, S.J. Gabryszewski, H.F. Rosenberg, Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 114, 2649–2656 (2009). https://doi.org/10.1182/blood-2009-01-199497 CrossRefPubMedPubMedCentral

B.K. Lo, M. Yu, D. Zloty, B. Cowan, J. Shapiro, K.J. McElwee, CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 176, 2435–2446 (2010). https://doi.org/10.2353/ajpath.2010.081059 CrossRefPubMedPubMedCentral

R. Altara, M. Manca, R.D. Brandao, A. Zeidan, G.W. Booz, F.A. Zouein, Emerging importance of chemokine receptor CXCR3 and its ligands in cardiovascular diseases. Clin Science 130, 463–478 (2016). https://doi.org/10.1042/cs20150666 CrossRef

M. Liu, S. Guo, J.K. Stiles, The emerging role of CXCL10 in cancer. Oncol Lett 2, 583–589 (2011). https://doi.org/10.3892/ol.2011.300 CrossRefPubMedPubMedCentral

10.

M.A. Garcia-Lopez, F. Sanchez-Madrid, J.M. Rodriguez-Frade, M. Mellado, A. Acevedo, M.I. Garcia, J.P. Albar, C. Martinez, M. Marazuela, CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Investig 81, 409–418 (2001). https://doi.org/10.1038/labinvest.3780248 CrossRefPubMed

11.

R. Tokunaga, W. Zhang, M. Naseem, A. Puccini, M.D. Berger, S. Soni, M. McSkane, H. Baba, H.J. Lenz, CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev 63, 40–47 (2018). https://doi.org/10.1016/j.ctrv.2017.11.007 CrossRefPubMed

12.

H. Nomiyama, N. Osada, O. Yoshie, The evolution of mammalian chemokine genes. Cytokine Gowth Fact Rev 21, 253–262 (2010). https://doi.org/10.1016/j.cytogfr.2010.03.004 CrossRef

13.

A.L. Angiolillo, C. Sgadari, D.D. Taub, F. Liao, J.M. Farber, S. Maheshwari, H.K. Kleinman, G.H. Reaman, G. Tosato, Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182, 155–162 (1995). https://doi.org/10.1084/jem.182.1.155 CrossRefPubMed

14.

L. Persano, M. Crescenzi, S. Indraccolo, Anti-angiogenic gene therapy of cancer: Current status and future prospects. Mol Asp Med 28, 87–114 (2007). https://doi.org/10.1016/j.mam.2006.12.005 CrossRef

15.

F. Antonicelli, J. Lorin, S. Kurdykowski, S.C. Gangloff, R. Le Naour, J.M. Sallenave, W. Hornebeck, F. Grange, P. Bernard, CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Brit J Dermatol 164, 720–728 (2011). https://doi.org/10.1111/j.1365-2133.2010.10176.x CrossRef

16.

G. Li, L. Tian, J.M. Hou, Z.Y. Ding, Q.M. He, P. Feng, Y.J. Wen, F. Xiao, B. Yao, R. Zhang, F. Peng, Y. Jiang, F. Luo, X. Zhao, L. Zhang, Q. Zhou, Y.Q. Wei, Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors. Clin Cancer Res 11, 4217–4224 (2005). https://doi.org/10.1158/1078-0432.ccr-04-2117 CrossRefPubMed

17.

M.L. Nagpal, J. Davis, T. Lin, Overexpression of CXCL10 in human prostate LNCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta 1762, 811–818 (2006). https://doi.org/10.1016/j.bbadis.2006.06.017 CrossRefPubMed

18.

H. Verbeke, K. Geboes, J. Van Damme, S. Struyf, The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta 1825, 117–129 (2012). https://doi.org/10.1016/j.bbcan.2011.10.008 CrossRefPubMed

19.

M. Zhao, Q. Ma, J. Xu, S. Fu, L. Chen, B. Wang, J. Wu, L. Yang, Combining CXCL10 gene therapy and radiotherapy improved therapeutic efficacy in cervical cancer HeLa cell xenograft tumor models. Oncol Lett 10, 768–772 (2015). https://doi.org/10.3892/ol.2015.3281 CrossRefPubMedPubMedCentral

20.

M. Enderlin, E.V. Kleinmann, S. Struyf, C. Buracchi, A. Vecchi, R. Kinscherf, F. Kiessling, S. Paschek, S. Sozzani, J. Rommelaere, J.J. Cornelis, J. Van Damme, C. Dinsart, TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther 16, 149–160 (2009). https://doi.org/10.1038/cgt.2008.62 CrossRefPubMed

21.

J.R. Schoenborn, C.B. Wilson, Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96, 41–101 (2007). https://doi.org/10.1016/s0065-2776(07)96002-2 CrossRefPubMed

22.

A.V. Gorbachev, H. Kobayashi, D. Kudo, C.S. Tannenbaum, J.H. Finke, S. Shu, J.M. Farber, R.L. Fairchild, CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J Immunol 178, 2278–2286 (2007). https://doi.org/10.4049/jimmunol.178.4.2278 CrossRefPubMed

23.

C. Qian, H. An, Y. Yu, S. Liu, X. Cao, TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 109, 3308–3315 (2007). https://doi.org/10.1182/blood-2006-08-040337 CrossRefPubMed

24.

Y. Ohmori, L. Wyner, S. Narumi, D. Armstrong, M. Stoler, T.A. Hamilton, Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am J Pathol 142, 861–870 (1993)PubMedPubMedCentral

25.

J.B. Xia, G.H. Liu, Z.Y. Chen, C.Z. Mao, D.C. Zhou, H.Y. Wu, K.S. Park, H. Zhao, S.K. Kim, D.Q. Cai, X.F. Qi, Hypoxia/ischemia promotes CXCL10 expression in cardiac microvascular endothelial cells by NFkB activation. Cytokine 81, 63–70 (2016). https://doi.org/10.1016/j.cyto.2016.02.007 CrossRefPubMed

26.

R.A. Colvin, G.S. Campanella, J. Sun, A.D. Luster, Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279, 30219–30227 (2004). https://doi.org/10.1074/jbc.M403595200 CrossRefPubMed

27.

S.C. Wightman, A. Uppal, S.P. Pitroda, S. Ganai, B. Burnette, M. Stack, G. Oshima, S. Khan, X. Huang, M.C. Posner, R.R. Weichselbaum, N.N. Khodarev, Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Brit J Cancer 113, 327–335 (2015). https://doi.org/10.1038/bjc.2015.193 CrossRefPubMedPubMedCentral

28.

S. Moriai, M. Takahara, T. Ogino, T. Nagato, K. Kishibe, H. Ishii, A. Katayama, N. Shimizu, Y. Harabuchi, Production of interferon-{gamma}-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T-cell lymphoma cells. Clin Cancer Res 15, 6771–6779 (2009). https://doi.org/10.1158/1078-0432.ccr-09-1052 CrossRefPubMed

29.

J. Vinet, E.K. de Jong, H.W. Boddeke, V. Stanulovic, N. Brouwer, I. Granic, U.L. Eisel, R.S. Liem, K. Biber, Expression of CXCL10 in cultured cortical neurons. J Neurochem 112, 703–714 (2010). https://doi.org/10.1111/j.1471-4159.2009.06495.x CrossRefPubMed

30.

T. Ren, L. Zhu, M. Cheng, XCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma. Am J Transl Res 9, 2824–2837 (2017)PubMedPubMedCentral

31.

A. Pellegrino, F. Antonaci, F. Russo, F. Merchionne, D. Ribatti, A. Vacca, F. Dammacco, CXCR3-binding chemokines in multiple myeloma. Cancer Lett 207, 221–227 (2004). https://doi.org/10.1016/j.canlet.2003.10.036 CrossRefPubMed

32.

M. Furuya, T. Suyama, H. Usui, Y. Kasuya, M. Nishiyama, N. Tanaka, I. Ishiwata, Y. Nagai, M. Shozu, S. Kimura, Up-regulation of CXC chemokines and their receptors: Implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 38, 1676–1687 (2007). https://doi.org/10.1016/j.humpath.2007.03.023 CrossRefPubMed

33.

M. Duruisseaux, N. Rabbe, M. Antoine, T. Vieira, V. Poulot, J. Cadranel, M. Wislez, Pro-tumoural CXCL10/CXCR3-a autocrine loop in invasive mucinous lung adenocarcinoma. ERJ Open Res 3, 00047–02016 (2017). https://doi.org/10.1183/23120541.00047-2016 CrossRefPubMedPubMedCentral

34.

D. Datta, J.A. Flaxenburg, S. Laxmanan, C. Geehan, M. Grimm, A.M. Waaga-Gasser, D.M. Briscoe, S. Pal, Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: Relevance for the development of human breast cancer. Cancer Res 66, 9509–9518 (2006). https://doi.org/10.1158/0008-5472.can-05-4345 CrossRefPubMed

35.

A.A. Ejaeidi, B.S. Craft, L.V. Puneky, R.E. Lewis, J.M. Cruse, Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Exp Mol Pathol 99, 163–172 (2015). https://doi.org/10.1016/j.yexmp.2015.06.002 CrossRefPubMed

36.

A. Antonelli, S.M. Ferrari, P. Fallahi, S. Frascerra, S. Piaggi, S. Gelmini, C. Lupi, M. Minuto, P. Berti, S. Benvenga, F. Basolo, C. Orlando, P. Miccoli, Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: Modulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrine Related Cancer 16, 1299–1311 (2009). https://doi.org/10.1677/erc-08-0337 CrossRefPubMed

37.

R.J. Flores, A.J. Kelly, Y. Li, M. Nakka, D.A. Barkauskas, M. Krailo, L.L. Wang, L. Perlaky, C.C. Lau, M.J. Hicks, T.K. Man, A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG. Cancer 123, 144–154 (2017). https://doi.org/10.1002/cncr.30272 CrossRefPubMed

38.

S. Lunardi, N.B. Jamieson, S.Y. Lim, K.L. Griffiths, M. Carvalho-Gaspar, O. Al-Assar, S. Yameen, R.C. Carter, C.J. McKay, G. Spoletini, S. D'Ugo, M.A. Silva, O.J. Sansom, K.P. Janssen, R.J. Muschel, T.B. Brunner, IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget 5, 11064–11080 (2014). https://doi.org/10.18632/oncotarget.2519 CrossRefPubMedPubMedCentral

39.

Y. Yamaguchi, V.J. Hearing, Melanocytes and their diseases (Cold Spring Harb. Perspect, Med, 2014). https://doi.org/10.1101/cshperspect.a017046 CrossRef

40.

H. Mirzaei, H. Salehi, R.K. Oskuee, A. Mohammadpour, H.R. Mirzaei, M.R. Sharifi, R. Salarinia, H.Y. Darani, M. Mokhtari, A. Masoudifar, A. Sahebkar, R. Salehi, M.R. Jaafari, The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model. Cancer Lett 419, 30–39 (2018). https://doi.org/10.1016/j.canlet.2018.01.029 CrossRefPubMed

41.

H. Mirzaei, A. Sahebkar, A. Avan, M.R. Jaafari, R. Salehi, H. Salehi, H. Baharvand, A. Rezaei, J. Hadjati, J.M. Pawelek, H.R. Mirzaei, Application of Mesenchymal stem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents. Curr Med Chem 23, 455–463 (2016). https://doi.org/10.2174/0929867323666151217122033 CrossRefPubMed

42.

D. Schadendorf, D.E. Fisher, C. Garbe, J.E. Gershenwald, J.J. Grob, A. Halpern, M. Herlyn, M.A. Marchetti, G. McArthur, A. Ribas, A. Roesch, A. Hauschild, Melanoma Nature Rev 1, 15003 (2015). https://doi.org/10.1038/nrdp.2015.3 CrossRef

43.

A.E. Chang, L.H. Karnell, H.R. Menck, The National Cancer Data Base report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. Cancer 83, 1664–1678 (1998). https://doi.org/10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g CrossRefPubMed

44.

B.A. Kohler, E. Ward, B.J. McCarthy, M.J. Schymura, L.A. Ries, C. Eheman, A. Jemal, R.N. Anderson, U.A. Ajani, B.K. Edwards, Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 103, 714–736 (2011). https://doi.org/10.1093/jnci/djr077 CrossRefPubMedPubMedCentral

45.

B. Domingues, J.M. Lopes, P. Soares, H. Populo, Melanoma treatment in review. ImmunoTargets Ther 7, 35–49 (2018). https://doi.org/10.2147/itt.s134842 CrossRefPubMedPubMedCentral

46.

M.S. Lawrence, P. Stojanov, P. Polak, G.V. Kryukov, K. Cibulskis, A. Sivachenko, S.L. Carter, C. Stewart, C.H. Mermel, S.A. Roberts, A. Kiezun, P.S. Hammerman, A. McKenna, Y. Drier, L. Zou, A.H. Ramos, T.J. Pugh, N. Stransky, E. Helman, J. Kim, C. Sougnez, L. Ambrogio, E. Nickerson, E. Shefler, M.L. Cortes, D. Auclair, G. Saksena, D. Voet, M. Noble, D. DiCara, P. Lin, L. Lichtenstein, D.I. Heiman, T. Fennell, M. Imielinski, B. Hernandez, E. Hodis, S. Baca, A.M. Dulak, J. Lohr, D.A. Landau, C.J. Wu, J. Melendez-Zajgla, A. Hidalgo-Miranda, A. Koren, S.A. McCarroll, J. Mora, B. Crompton, R. Onofrio, M. Parkin, W. Winckler, K. Ardlie, S.B. Gabriel, C.W.M. Roberts, J.A. Biegel, K. Stegmaier, A.J. Bass, L.A. Garraway, M. Meyerson, T.R. Golub, D.A. Gordenin, S. Sunyaev, E.S. Lander, G. Getz, Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013). https://doi.org/10.1038/nature12213 CrossRefPubMedPubMedCentral

47.

F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424 (2018). https://doi.org/10.3322/caac.21492 CrossRefPubMed

48.

R. De Angelis, M. Sant, M.P. Coleman, S. Francisci, P. Baili, D. Pierannunzio, A. Trama, O. Visser, H. Brenner, E. Ardanaz, M. Bielska-Lasota, G. Engholm, A. Nennecke, S. Siesling, F. Berrino, R. Capocaccia, Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE--5-a population-based study. Lancet Oncol 15, 23–34 (2014). https://doi.org/10.1016/s1470-2045(13)70546-1 CrossRefPubMed

49.

M. Tamaru, K. Tomura, S. Sakamoto, K. Tezuka, T. Tamatani, S. Narumi, Interleukin-1beta induces tissue- and cell type-specific expression of adhesion molecules in vivo. Arterioscler Thromb Vasc Biol 18, 1292–1303 (1998). https://doi.org/10.1161/01.atv.18.8.1292 CrossRefPubMed

50.

M.F. Hsieh, S.L. Lai, J.P. Chen, J.M. Sung, Y.L. Lin, B.A. Wu-Hsieh, C. Gerard, A. Luster, F. Liao, Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J Immunol 177, 1855–1863 (2006). https://doi.org/10.4049/jimmunol.177.3.1855 CrossRefPubMed

51.

S.G. Kelsen, M.O. Aksoy, Y. Yang, S. Shahabuddin, J. Litvin, F. Safadi, T.J. Rogers, The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. American journal of physiology Lung Cell Mol Physiol 287, L584–L591 (2004). https://doi.org/10.1152/ajplung.00453.2003 CrossRef

52.

A.D. Luster, J.C. Unkeless, J.V. Ravetch, Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672–676 (1985). https://doi.org/10.1038/315672a0 CrossRefPubMed

53.

Y.A. Berchiche, T.P. Sakmar, CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways. Mol Pharmacol 90, 483–495 (2016). https://doi.org/10.1124/mol.116.105502 CrossRefPubMed

54.

M. Loetscher, B. Gerber, P. Loetscher, S.A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, B. Moser, Chemokine receptor specific for IP10 and mig: Structure, function, and expression in activated T-lymphocytes. J Exp Med 184, 963–969 (1996). https://doi.org/10.1084/jem.184.3.963 CrossRefPubMed

55.

C. Yang, W. Zheng, W. Du, CXCR3A contributes to the invasion and metastasis of gastric cancer cells. Oncol Rep 36, 1686–1692 (2016). https://doi.org/10.3892/or.2016.4953 CrossRefPubMed

56.

L. Lasagni, M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, F. Marra, S. Romagnani, M. Serio, P. Romagnani, An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197, 1537–1549 (2003). https://doi.org/10.1084/jem.20021897 CrossRefPubMedPubMedCentral

57.

C. Billottet, C. Quemener, A. Bikfalvi, CXCR3, a double-edged sword in tumor progression and angiogenesis. Biochim Biophys Acta 1836, 287–295 (2013). https://doi.org/10.1016/j.bbcan.2013.08.002 CrossRefPubMed

58.

G.S. Campanella, B.D. Medoff, L.A. Manice, R.A. Colvin, A.D. Luster, Development of a novel chemokine-mediated in vivo T cell recruitment assay. J Immunol Meth 331, 127–139 (2008). https://doi.org/10.1016/j.jim.2007.12.002 CrossRef

59.

A. Martin-Fontecha, L.L. Thomsen, S. Brett, C. Gerard, M. Lipp, A. Lanzavecchia, F. Sallusto, Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nature Immunol 5, 1260–1265 (2004). https://doi.org/10.1038/ni1138 CrossRef

60.

X. Yang, Y. Chu, Y. Wang, R. Zhang, S. Xiong, Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J Leuk Biol 80, 1434–1444 (2006). https://doi.org/10.1189/jlb.0306212 CrossRef

61.

M.J. Smyth, E. Cretney, M.H. Kershaw, Y. Hayakawa, Cytokines in cancer immunity and immunotherapy. Immunol Rev 202, 275–293 (2004). https://doi.org/10.1111/j.0105-2896.2004.00199.x CrossRefPubMed

62.

S.C. Robinson, L.M. Coussens, Soluble mediators of inflammation during tumor development. Adv Cancer Res 93, 159–187 (2005). https://doi.org/10.1016/s0065-230x(05)93005-4 CrossRefPubMed

63.

F. Balkwill, A. Mantovani, Inflammation and cancer: Back to Virchow? Lancet 357, 539–545 (2001). https://doi.org/10.1016/s0140-6736(00)04046-0 CrossRefPubMed

64.

J.M. Wang, X. Deng, W. Gong, S. Su, Chemokines and their role in tumor growth and metastasis. J Immunol Meth 220, 1–17 (1998). https://doi.org/10.1016/s0022-1759(98)00128-8 CrossRef

65.

K.E. de Visser, A. Eichten, L.M. Coussens, Paradoxical roles of the immune system during cancer development. Nature Rev Cancer 6, 24–37 (2006). https://doi.org/10.1038/nrc1782 CrossRef

66.

Y. Ouyang, K. Liu, M. Hao, R. Zheng, C. Zhang, Y. Wu, X. Zhang, N. Li, J. Zheng, D. Chen, Radiofrequency ablation-increased CXCL10 is associated with earlier recurrence of hepatocellular carcinoma by promoting stemness. Tumour Biol 37, 3697–3704 (2016). https://doi.org/10.1007/s13277-015-4035-5 CrossRefPubMed

67.

K. Kawada, H. Hosogi, M. Sonoshita, H. Sakashita, T. Manabe, Y. Shimahara, Y. Sakai, A. Takabayashi, M. Oshima, M.M. Taketo, Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 26, 4679–4688 (2007). https://doi.org/10.1038/sj.onc.1210267 CrossRefPubMed

68.

C. Liu, D. Luo, B.A. Reynolds, G. Meher, A.R. Katritzky, B. Lu, C.J. Gerard, C.P. Bhadha, J.K. Harrison, Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 32, 129–137 (2011). https://doi.org/10.1093/carcin/bgq224 CrossRefPubMed

69.

S.V. Maru, K.A. Holloway, G. Flynn, C.L. Lancashire, A.J. Loughlin, D.K. Male, I.A. Romero, Chemokine production and chemokine receptor expression by human glioma cells: Role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199, 35–45 (2008). https://doi.org/10.1016/j.jneuroim.2008.04.029 CrossRefPubMed

70.

M. Loetscher, P. Loetscher, N. Brass, E. Meese, B. Moser, Lymphocyte-specific chemokine receptor CXCR3: Regulation, chemokine binding and gene localization. Eur J Immunol 28, 3696–3705 (1998). https://doi.org/10.1002/(sici)1521-4141(199811)28:11<3696::aid-immu3696>3.0.co;2-w CrossRefPubMed

71.

A. Marusyk, K. Polyak, Tumor heterogeneity: Causes and consequences. Biochim Biophys Acta 1805, 105–117 (2010). https://doi.org/10.1016/j.bbcan.2009.11.002 CrossRefPubMed

72.

T.J. Zumwalt, M. Arnold, A. Goel, C.R. Boland, Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration. Oncotarget 6, 2981–2991 (2015). https://doi.org/10.18632/oncotarget.3205 CrossRefPubMed

73.

J.H. Dufour, M. Dziejman, M.T. Liu, J.H. Leung, T.E. Lane, A.D. Luster, IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168, 3195–3204 (2002). https://doi.org/10.4049/jimmunol.168.7.3195 CrossRefPubMed

74.

M. Rentoft, P.J. Coates, L. Loljung, T. Wilms, G. Laurell, K. Nylander, Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue. Tumour Biol 35, 4191–4198 (2014). https://doi.org/10.1007/s13277-013-1549-6 CrossRefPubMed

75.

H. Bronger, J. Singer, C. Windmuller, U. Reuning, D. Zech, C. Delbridge, J. Dorn, M. Kiechle, B. Schmalfeldt, M. Schmitt, S. Avril, CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Brit J Cancer 115, 553–563 (2016). https://doi.org/10.1038/bjc.2016.172 CrossRefPubMedPubMedCentral

76.

A.G. Cuenca, J.L. Wynn, K.M. Kelly-Scumpia, P.O. Scumpia, L. Vila, M.J. Delano, C.E. Mathews, S.M. Wallet, W.H. Reeves, K.E. Behrns, D.C. Nacionales, P.A. Efron, S.L. Kunkel, L.L. Moldawer, Critical role for CXC ligand 10/CXC receptor 3 signaling in the murine neonatal response to sepsis. Infect Immunol 79, 2746–2754 (2011). https://doi.org/10.1128/iai.01291-10 CrossRef

77.

J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, H. Kutzner, K.H. Cho, S. Aiba, E.B. Brocker, P.E. LeBoit, D. Pinkel, B.C. Bastian, Distinct sets of genetic alterations in melanoma. New Engl J Med 353, 2135–2147 (2005). https://doi.org/10.1056/NEJMoa050092 CrossRefPubMed

78.

M. Winder, A. Viros, Mechanisms of drug resistance in melanoma. Handbook Exp Pharmacol 249, 91–108 (2018). https://doi.org/10.1007/164_2017_17 CrossRef

79.

P. Sharma, J.P. Allison, Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 161, 205–214 (2015). https://doi.org/10.1016/j.cell.2015.03.030 CrossRefPubMedPubMedCentral

80.

K. Wing, Y. Onishi, P. Prieto-Martin, T. Yamaguchi, M. Miyara, Z. Fehervari, T. Nomura, S. Sakaguchi, CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008). https://doi.org/10.1126/science.1160062 CrossRefPubMed

81.

Y. Latchman, C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A.J. Long, J.A. Brown, R. Nunes, E.A. Greenfield, K. Bourque, V.A. Boussiotis, L.L. Carter, B.M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A.H. Sharpe, G.J. Freeman, PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunol 2, 261–268 (2001). https://doi.org/10.1038/85330 CrossRef

82.

R.J. Greenwald, Y.E. Latchman, A.H. Sharpe, Negative co-receptors on lymphocytes. Curr Opin Immunol 14, 391–396 (2002). https://doi.org/10.1016/s0952-7915(02)00341-2 CrossRefPubMed

83.

X. Jiang, J. Wang, X. Deng, F. Xiong, J. Ge, B. Xiang, X. Wu, J. Ma, M. Zhou, X. Li, Y. Li, G. Li, W. Xiong, C. Guo, Z. Zeng, Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer 18, 10 (2019). https://doi.org/10.1186/s12943-018-0928-4 CrossRefPubMedPubMedCentral

84.

J. Larkin, F.S. Hodi, J.D. Wolchok, Combined Nivolumab and Ipilimumab or Monotherapy in untreated melanoma. New Engl J Med 373, 1270–1271 (2015). https://doi.org/10.1056/NEJMc1509660 CrossRefPubMed

85.

B. Escudier, P. Sharma, D.F. McDermott, S. George, H.J. Hammers, S. Srinivas, S.S. Tykodi, J.A. Sosman, G. Procopio, E.R. Plimack, D. Castellano, H. Gurney, F. Donskov, K. Peltola, J. Wagstaff, T.C. Gauler, T. Ueda, H. Zhao, I.M. Waxman, R.J. Motzer, Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962–71]. Eur Urol 73, e116–e118 (2018). https://doi.org/10.1016/j.eururo.2017.12.016 CrossRefPubMed

86.

U. Barash, Y. Zohar, G. Wildbaum, K. Beider, A. Nagler, N. Karin, N. Ilan, I. Vlodavsky, Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia 28, 2178–2187 (2014). https://doi.org/10.1038/leu.2014.121 CrossRefPubMedPubMedCentral

87.

M.R. Zamani, S. Aslani, A. Salmaninejad, M.R. Javan, N. Rezaei, PD-1/PD-L and autoimmunity: A growing relationship. Cell Immunol 310, 27–41 (2016). https://doi.org/10.1016/j.cellimm.2016.09.009 CrossRefPubMed

88.

B. Zhang, S. Chikuma, S. Hori, S. Fagarasan, T. Honjo, Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci U S A 113, 8490–8495 (2016). https://doi.org/10.1073/pnas.1608873113 CrossRefPubMedPubMedCentral

89.

E. Ramelyte, S.A. Schindler, R. Dummer, The safety of anti PD-1 therapeutics for the treatment of melanoma. Exp Opin Drug Safety 16, 41–53 (2017). https://doi.org/10.1080/14740338.2016.1248402 CrossRef

90.

D.A. Arenberg, E.S. White, M.D. Burdick, S.R. Strom, R.M. Strieter, Improved survival in tumor-bearing SCID mice treated with interferon-gamma-inducible protein 10 (IP-10/CXCL10). Cancer Immunol Immunother 50, 533–538 (2001). https://doi.org/10.1007/s00262-001-0231-9 CrossRefPubMed

91.

Y. Toiyama, H. Fujikawa, M. Kawamura, K. Matsushita, S. Saigusa, K. Tanaka, Y. Inoue, K. Uchida, Y. Mohri, M. Kusunoki, Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 40, 560–566 (2012). https://doi.org/10.3892/ijo.2011.1247 CrossRefPubMed

92.

R. Khanmohammadi, F. Mir, G. Baniebrahimi, Oral tumors in children: Diagnosis and management. J Cell Biochem 119, 2474–2483 (2018). https://doi.org/10.1002/jcb.26316 CrossRefPubMed

93.

H. Harlin, Y. Meng, A.C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, T.F. Gajewski, Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69, 3077–3085 (2009). https://doi.org/10.1158/0008-5472.can-08-2281 CrossRefPubMed

94.

M. Neagu, C. Constantin, C. Longo, Chemokines in the melanoma metastasis biomarkers portrait. J Immunoassay Immunochemistry 36, 559–566 (2015). https://doi.org/10.1080/15321819.2015.1035593 CrossRef

95.

H. Kobayashi, Y. Nobeyama, H. Nakagawa, Tumor-suppressive effects of natural-type interferon-beta through CXCL10 in melanoma. Biochem Biophys Res Comm 464, 416–421 (2015). https://doi.org/10.1016/j.bbrc.2015.06.122 CrossRefPubMed

96.

G.M. Wiedemann, C. Aithal, A. Kraechan, C. Heise, B.L. Cadilha, J. Zhang, P. Duewell, R. Ballotti, S. Endres, C. Bertolotto, S. Kobold, Microphthalmia-associated transcription factor (MITF) regulates immune cell migration into melanoma. Transl Oncol 12, 350–360 (2019). https://doi.org/10.1016/j.tranon.2018.10.014 CrossRefPubMed

97.

D. D'Arcangelo, F. Facchiano, G. Nassa, A. Stancato, A. Antonini, S. Rossi, C. Senatore, M. Cordella, C. Tabolacci, A. Salvati, R. Tarallo, A. Weisz, A.M. Facchiano, A. Facchiano, PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget 7, 77257–77275 (2016). https://doi.org/10.18632/oncotarget.12629 CrossRefPubMedPubMedCentral

98.

A. Kawamata, D. Ito, T. Odani, T. Isobe, M. Iwase, M. Hatori, M. Nagumo, Thalidomide suppresses melanoma growth by activating natural killer cells in mice. Oncol Rep 16, 1231–1236 (2006)PubMed

99.

A. Szabo, R.M. Osman, I. Bacskai, B.V. Kumar, Z. Agod, A. Lanyi, P. Gogolak, E. Rajnavolgyi, Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNbeta secretion controlled differently by TLR3 and MDA5. Melanoma Res 22, 351–361 (2012). https://doi.org/10.1097/CMR.0b013e328357076c CrossRefPubMed

100.

W. Peng, C. Liu, C. Xu, Y. Lou, J. Chen, Y. Yang, H. Yagita, W.W. Overwijk, G. Lizee, L. Radvanyi, P. Hwu, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 72, 5209–5218 (2012). https://doi.org/10.1158/0008-5472.can-12-1187 CrossRefPubMedPubMedCentral

101.

Z.S. Chheda, R.K. Sharma, V.R. Jala, A.D. Luster, B. Haribabu, Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors. J Immunol 197, 2016–2026 (2016). https://doi.org/10.4049/jimmunol.1502376 CrossRefPubMed

102.

R.R. Ji, S.D. Chasalow, L. Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N.O. Siemers, J.R. Jackson, V. Shahabi, An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61, 1019–1031 (2012). https://doi.org/10.1007/s00262-011-1172-6 CrossRefPubMed

103.

R. Barreira da Silva, M.E. Laird, N. Yatim, L. Fiette, M.A. Ingersoll, M.L. Albert, Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nature Immunol 16, 850–858 (2015). https://doi.org/10.1038/ni.3201 CrossRef

104.

Y. Li, M. Fang, J. Zhang, J. Wang, Y. Song, J. Shi, W. Li, G. Wu, J. Ren, Z. Wang, W. Zou, L. Wang, Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology 5, e1074374 (2016). https://doi.org/10.1080/2162402x.2015.1074374 CrossRefPubMed

105.

M. Hong, A.L. Puaux, C. Huang, L. Loumagne, C. Tow, C. Mackay, M. Kato, A. Prevost-Blondel, M.F. Avril, A. Nardin, J.P. Abastado, Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71, 6997–7009 (2011). https://doi.org/10.1158/0008-5472.can-11-1466 CrossRefPubMed

106.

D. Bedognetti, T.L. Spivey, Y. Zhao, L. Uccellini, S. Tomei, M.E. Dudley, M.L. Ascierto, V. De Giorgi, Q. Liu, L.G. Delogu, M. Sommariva, M.R. Sertoli, R. Simon, E. Wang, S.A. Rosenberg, F.M. Marincola, CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Brit J Cancer 109, 2412–2423 (2013). https://doi.org/10.1038/bjc.2013.557 CrossRefPubMedPubMedCentral

107.

F. Ulloa-Montoya, J. Louahed, B. Dizier, O. Gruselle, B. Spiessens, F.F. Lehmann, S. Suciu, W.H. Kruit, A.M. Eggermont, J. Vansteenkiste, V.G. Brichard, Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 31, 2388–2395 (2013). https://doi.org/10.1200/jco.2012.44.3762 CrossRefPubMed

Title: CXCL-10: a new candidate for melanoma therapy?
Authors: Hossein Bagheri
Mohammad Hossein Pourhanifeh
Maryam Derakhshan
Maryam Mahjoubin-Tehran
Faezeh Ghasemi
Shabnam Mousavi
Rouhollah Rafiei
Kazem Abbaszadeh-Goudarzi
Hamid Reza Mirzaei
Hamed Mirzaei
Publication date: 01-06-2020
Publisher: Springer Netherlands
Keywords: Metastasis
Melanoma
Melanoma
Published in: Cellular Oncology / Issue 3/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-020-00501-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Long noncoding RNA LINC01234 silencing exerts an anti-oncogenic effect in esophageal cancer cells through microRNA-193a-5p-mediated CCNE1 downregulation

Insulinoma-associated protein 1 (INSM1): a potential biomarker and therapeutic target for neuroendocrine tumors

Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer

FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer

Dp44mT, an iron chelator, suppresses growth and induces apoptosis via RORA-mediated NDRG2-IL6/JAK2/STAT3 signaling in glioma

Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms

Keynote webinar | Spotlight on antibody–drug conjugates in cancer